Comorbidities, multimorbidity and COVID-19
The influence of comorbidities on COVID-19 outcomes has been recognized since the
earliest days of the pandemic. But establishing causality and determining underlying …
earliest days of the pandemic. But establishing causality and determining underlying …
Long COVID: an overview
AV Raveendran, R Jayadevan… - Diabetes & Metabolic …, 2021 - Elsevier
Background and aims Long COVID is the collective term to denote persistence of symptoms
in those who have recovered from SARS-CoV-2 infection. Methods WE searched the …
in those who have recovered from SARS-CoV-2 infection. Methods WE searched the …
[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
B Killingley, AJ Mann, M Kalinova, A Boyers… - Nature Medicine, 2022 - nature.com
Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
2) has caused hundreds of millions of cases and continues to circulate globally. To establish …
A common allele of HLA is associated with asymptomatic SARS-CoV-2 infection
DG Augusto, LD Murdolo, DSM Chatzileontiadou… - Nature, 2023 - nature.com
Studies have demonstrated that at least 20% of individuals infected with SARS-CoV-2
remain asymptomatic,,–. Although most global efforts have focused on severe illness in …
remain asymptomatic,,–. Although most global efforts have focused on severe illness in …
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19
J Hammond, H Leister-Tebbe, A Gardner… - … England Journal of …, 2022 - Mass Medical Soc
Background Nirmatrelvir is an orally administered severe acute respiratory syndrome
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …
coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in …
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
RA Evans, H McAuley, EM Harrison… - The Lancet …, 2021 - thelancet.com
Background The impact of COVID-19 on physical and mental health and employment after
hospitalisation with acute disease is not well understood. The aim of this study was to …
hospitalisation with acute disease is not well understood. The aim of this study was to …
[PDF][PDF] Therapeutics and COVID-19: living guideline, 13 January 2023
World Health Organization - 2023 - apps.who.int
As of December 2022, there have been over 642 million confirmed cases of COVID-19 (10).
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
The pandemic has thus far claimed approximately 6.62 million lives (10). Vaccination is …
Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS …
Importance Continuous positive airway pressure (CPAP) and high-flow nasal oxygen
(HFNO) have been recommended for acute hypoxemic respiratory failure in patients with …
(HFNO) have been recommended for acute hypoxemic respiratory failure in patients with …
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2,
there is little information about vaccine efficacy against variants of concern (VOC) in …
there is little information about vaccine efficacy against variants of concern (VOC) in …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …